Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma1Contributed equally

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 3, 2015, Pages 113.e9-113.e17

  Zhou, Jiancheng ^a   Deng, Zhuo ^a   Chen, Yule ^a   Gao, Yang ^a   Wu, Dapeng ^a   Zhu, Guodong ^a   Li, Lei ^a   Song, Wenbin ^a   Wang, Xinyang ^a   Wu, Kaijie ^a   He, Dalin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Cell growth; FABP7; Gene profile; Prognostic factor; Renal cell carcinoma

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; STAT3 PROTEIN; CARRIER PROTEIN; FABP7 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CLONOGENESIS; CONTROLLED STUDY; DNA METHYLATION; FATTY ACID BINDING PROTEIN 7 GENE; FEMALE; GENE; GENE DOSAGE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; AGED; CELL CYCLE; CLUSTER ANALYSIS; COHORT ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; KIDNEY TUMOR; METABOLISM; MIDDLE AGED; MUTATION; PROGNOSIS; RETROSPECTIVE STUDY; TISSUE MICROARRAY; TUMOR CELL LINE; TUMOR RECURRENCE; UPREGULATION;

AGED; CARCINOMA, RENAL CELL; CARRIER PROTEINS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTER ANALYSIS; COHORT STUDIES; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 85003053635     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.08.001     Document Type: Article

References (35)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
2. Cohen H.T., McGovern F.J. Renal-cell carcinoma. N Engl J Med 2005, 353:2477-2490.
3. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013, 499:43-49. Cancer Genome Atlas Research Network.
4. Sato Y., Yoshizato T., Shiraishi Y., et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 2013, 45:860-867.
5. Gerlinger M., Horswell S., Larkin J., et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014, 46:225-233.
6. Lindor N.M., Dechet C.B., Greene M.H., et al. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population. Genet Test 2001, 5:101-106.
7. Gesk S., Siebert R., Wacker H.H., et al. Lack of deletions of the PTEN/MMAC1 and MXI1 loci in renal cell carcinoma by interphase cytogenetics. Cancer Genet Cytogenet 2000, 118:87-88.
8. Kucejova B., Pena-Llopis S., Yamasaki T., et al. Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. Mol Cancer Res 2011, 9:1255-1265.
9. Pena-Llopis S., Vega-Rubin-de-Celis S., Liao A., et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012, 44:751-759.
10. Varela I., Tarpey P., Raine K., et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011, 469:539-542.
11. Baldewijns M.M., van Vlodrop I.J., Vermeulen P.B., et al. VHL and HIF signalling in renal cell carcinogenesis. J Pathol 2010, 221:125-138.
12. Gatto F., Nookaew I., Nielsen J. Chromosome 3p loss of heterozygosity is associated with a unique metabolic network in clear cell renal carcinoma. Proc Natl Acad Sci U S A 2014, 111:E866-E875.
13. Liu R.Z., Denovan-Wright E.M., Wright J.M. Structure, mRNA expression and linkage mapping of the brain-type fatty acid-binding protein gene (FABP7) from zebrafish (Danio rerio). Eur J Biochem 2003, 270:715-725.
14. Zendzian-Piotrowska M., Gorski J. Fatty acid binding protein (FABP). Postepy Hig Med Dosw 1994, 48:753-761.
15. Metallo C.M., Gameiro P.A., Bell E.L., et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2012, 481:380-384.
16. Glaysher J. Lipid metabolism and cancer. Curr Opin Lipidol 2013, 24:530-531.
17. Horiguchi A., Asano T., Asano T., et al. Pharmacological inhibitor of fatty acid synthase suppresses growth and invasiveness of renal cancer cells. J Urol 2008, 180:729-736.
18. Cerami E., Gao J., Dogrusoz U., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012, 2:401-404.
19. Bamford S., Dawson E., Forbes S., et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004, 91:355-358.
20. Wu K., Xie D., Zou Y., et al. The mechanism of DAB2IP in chemoresistance of prostate cancer cells. Clin Cancer Res. 2013, 19:4740-4749.
21. Zhang H., Rakha E.A., Ball G.R., et al. The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. Breast Cancer Res Treat 2010, 121:41-51.
22. Goto Y., Koyanagi K., Narita N., et al. Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma. J Invest Dermatol 2010, 130:221-229.
23. Goto Y., Matsuzaki Y., Kurihara S., et al. A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy. Cancer Res 2006, 66:4443-4449.
24. Oka H., Chatani Y., Hoshino R., et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 1995, 55:4182-4187.
25. Horiguchi A., Oya M., Shimada T., et al. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol 2002, 168:762-765.
26. Kim W.Y., Kaelin W.G. Role of VHL gene mutation in human cancer. J Clin Oncol 2004, 22:4991-5004.
27. Decker H.J., Gemmill R.M., Neumann H.P., et al. Loss of heterozygosity on 3p in a renal cell carcinoma in von Hippel-Lindau syndrome. Cancer Genet Cytogenet 1989, 39:289-293.
28. Ricketts C.J., Morris M.R., Gentle D., et al. Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma. Clin Epigenetics 2013, 5:16.
29. Semenza G.L. HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr 2007, 39:231-234.
30. Gordan J.D., Lal P., Dondeti V.R., et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008, 14:435-446.
31. Kim H., Zhang H., Meng D., et al. UAS domain of Ubxd8 and FAF1 polymerizes upon interaction with long-chain unsaturated fatty acids. J Lipid Res 2013, 54:2144-2152.
32. Liang Y., Diehn M., Watson N., et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 2005, 102:5814-5819.
33. Domoto T., Miyama Y., Suzuki H., et al. Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma. Cancer Sci 2007, 98:77-82.
34. Takaoka N., Takayama T., Teratani T., et al. Analysis of the regulation of fatty acid binding protein 7 expression in human renal carcinoma cell lines. BMC. Mol Biol 2011, 12:31.
35. Rini B.I., Atkins M.B. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009, 10:992-1000.